Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 11/20 | 0.89 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.89 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.89 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 7/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.83 |
| ▸ | GBA1 | P04062 | 2/20 | 0.83 |
| ▸ | ATM | Q13315 | 1/20 | 0.83 |
| ▸ | LMNA | P02545 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.74 |
| ▸ | TSHR | P16473 | 3/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.74 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7277479 | 0.94 | PDE5A (1.00) | PDE5APTGS1TBXAS1PTGS2MEN1 | |
| SCHEMBL1083763 | 0.91 | PDE5A (1.00) | PDE5APTGS1TBXAS1PTGS2MEN1 | |
| SCHEMBL1063668 | 0.91 | PDE5A (0.81) | PDE5APTGS1TBXAS1PTGS2MEN1 | |
| SCHEMBL3459669 | 0.89 | PDE5A (0.85) | PDE5APTGS1TBXAS1PTGS2MEN1 | |
| SCHEMBL13252155 | 0.88 | PDE5A (0.83) | PDE5APTGS1TBXAS1PTGS2MEN1 | |
| SCHEMBL2583554 | 0.86 | MEN1 (1.00) | PDE5APTGS1TBXAS1PTGS2MEN1 | |
| SCHEMBL1064854 | 0.85 | CYP1A2 (1.00) | PDE5APTGS1TBXAS1PTGS2MEN1 | |
| SCHEMBL7286130 | 0.85 | PDE5A (1.00) | PDE5APTGS1TBXAS1PTGS2MEN1 | |
| SCHEMBL2591972 | 0.84 | PDE5A (1.00) | PDE5APTGS1TBXAS1PTGS2MEN1 | |
| SCHEMBL4857376 | 0.84 | MEN1 (0.81) | PDE5APTGS1TBXAS1PTGS2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7597884-B2 | Hyperglycosylated polypeptide variants and methods of use | ALIOS BIOPHARMA, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2093235-A1 | Hyperglycosylated variants of interferon alfacon-1 | Alios Biopharma Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1789074-A4 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1987060-A2 | SYNTHETIC HYPERGLYCOSYLATED, AND HYPERGLYCOSYLATED PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7345045-B2 | Pyrido-pyrimidine compounds as medicaments | SCIOS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345045-B2 | Pyrido-pyrimidine compounds as medicaments | SCIOS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2007092537-A2 | SYNTHETIC HYPERGLYCOSYLATED, AND HYPERGLYCOSYLATED PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1789074-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2005110455-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050220784-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050171123-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2005-08-04 | — | — | US | disclosed |
| US-6903096-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| CN-1152867-C | Quinazoline derivatives as medicaments | �����ɷ� | 2004-06-09 | — | — | CN | disclosed |
| US-6476031-B1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2002-11-05 | — | — | US | disclosed |
| CN-1333757-A | Quinazoline derivatives as medicaments | SCIOS INC (US) | 2002-01-30 | — | — | CN | disclosed |
| US-6277989-B1 | USEFUL IN TREATING CONDITIONS THAT ARE CHARACTERIZED BY ENHANCED P38 KINASE ACTIVITY AND/OR TRANSFORMING GROWTH FACTOR BETA (TGF-.BETA.) ACTIVITY SUCH AS INFLAMMATION, PROLIFERATIVE DISEASES, AND CERTAIN CARDIOVASCULAR DISORDERS | SCIOS, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6184226-B1 | ANTIINFLAMMATORY AGENTS FOR TREATMENT OF CARDIOVASCULAR SYSTEM DISORDERS/RESPIRATORY SYSTEM DISORDERS, ANTIISCHEMIC AGENTS | SCIOS INC. | 2001-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | IFNAR1, IDE, CTSC | PDE5A 1222/4885PTGS1 1969/4885TBXAS1 4086/4885 |
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | IFNAR1, EPOR, HBB | PDE5A 1701/4885PTGS1 1418/4885TBXAS1 3625/4885 |
| US-20050171123-A1 | Quinazoline derivatives as medicaments | TGFBR2, SMAD2, ADRB2 | PDE5A 1211/4885PTGS1 598/4885TBXAS1 2062/4885 |
| US-20050220784-A1 | Quinazoline derivatives as medicaments | TGFBR2, SMAD2, ADRB2 | PDE5A 1211/4885PTGS1 598/4885TBXAS1 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.